

# Case-Control Study on Parkinson's Disease Among Mutualité Sociale Agricole Affiliates in Five Départements

<https://www.neurodegenerationresearch.eu/survey/case-control-study-on-parkinsons-disease-among-mutualite-sociale-agricole-affiliates-in-five-departements-2/>

## **Title of study**

Case-Control Study on Parkinson's Disease Among Mutualité Sociale Agricole Affiliates in Five Départements

## **Acronym for cohort**

TERRE

## **Name of Principal Investigator - Title**

Dr

## **Name of Principal Investigator - First name**

Alexis

## **Name of Principal Investigator - Last name**

Elbaz

## **Address of institution -Institution**

INSERM

## **Address of institution - Street address**

16 Avenue Paul Vaillant Couturier

## **Address of institution - City**

VILLEJUIF

## **Address of institution - Postcode**

94807

## **Country**

France

## **Website**

**Contact email**

[email protected]

**Funding source**

ANR - ANSES - France Parkinson

**Q1a. Please indicate below if your cohort includes or expects to include, incidence of the following conditions?**

Parkinson's disease

**Q2a. In a single sentence what is the stated aim of the study? (Maximum 30 words)**

To study the association of professional exposure to pesticides with Parkinson's disease and the role of gene-environment interactions

**Q2b. What distinguishes this case-control study from other studies?**

Detailed individual data on professional exposure to pesticides in farmers. Population-based study.

**Q3a. i) Number of publications that involve use of your cohort to date**

15

**Q3a. ii) Please give up to three examples of studies to date (PI, Institution, Title of Study)****Q3b. If data on research outputs are already available please paste the publication list/other data or provide a link to where these data are publicly available**

1. Chapuis, J., F. Moisan, G. Mellick, A. Elbaz, P. Silburn, F. Pasquier, D. Hannequin, C. Lendon, D. Campion, P. Amouyel and J. C. Lambert (2008). "Association study of the NEDD9 gene with the risk of developing Alzheimer's and Parkinson's disease." *Hum Mol. Genet* 17(18): 2863-2867. 2. Dutheil, F., P. Beaune, C. Tzourio, M.-A. Lorient and A. Elbaz (2010). "Interaction between ABCB1 and professional exposure to organochlorine insecticides in Parkinson's disease." *Arch. Neurol* 67(6): 739-745. 3. Elbaz, A., J. Clavel, P. J. Rathouz, F. Moisan, J. P. Galanaud, B. Delemotte, A. Alperovitch and C. Tzourio (2009). "Professional exposure to pesticides and Parkinson's disease." *Ann Neurol* 66: 494-504.

**Q3c. If no research has been done as yet, please explain in a few sentences what information (i.e. research findings) you expect will be gained from the case-control study****Q4a. Study criteria: what is the age range of participants at recruitment? Age in years From:**

18

**Q4a. Study criteria: what is the age range of participants at recruitment? To:**

**Q4b. Study criteria: what are the inclusion criteria?**

Case subjects: first LDD requests for Parkinson's disease (18-75 years old). Controls: treatment guarantee requests (random); matched to cases according to age, gender, and département of residence.

**Q4c. Study criteria: what are the exclusion criteria?**

**Q5a. What is the size of the cohort (i.e. how many participants have enrolled)?**

1-1,000

**Q5b. What is the expected number of control participants?**

501-1,000

**Q6a. Please describe what measures are used to characterise participants**

Clinical examination

**Q6b. Are there additional measures for participants with the clinical disorder?**

MMSE

**Q6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)?**

No

If YES please specify

**Q7. What is the study design?**

Nested case control

**Q8. Are your cases matched by**

Age|Sex

**Q9a. Does your study includes a specialised subset of control participants?**

No

**Q9b. If your study includes a specialised subset of control participants please describe**

**Q10a. Is data collection for this study**

Closed to new patients

**Q10b. If data collection is ongoing, are there plans to continue the cohort study beyond the current projected end date?**

**Q11. Are data collected**

Only through the study

**Q12. Is there a system in place to enable re-contact with patients for future studies?**

No

**Q13a. Please give information on data stored in a database (1)**

Data summarised in database

% Available

**Q13a. Please give information on data stored in a database (2)**

% Available

**Q13a. Please give information on data stored in a database (3)**

% Available

**Q13a. Please give information on data stored in a database (4)**

% Available

**Q13a. Please give information on data stored in a database (5)**

% Available

Please specify language used

% Available

**Q13b. Please give information on how data is held as individual records**

% Available

**Q14a. Are data available to other groups?**

Yes

**Q14b. If data is available to other groups what is the access policy/mechanisms for access?**

Access through collaboration with PI only

**Q15. What data sharing policy is specified as a condition of use?**

No policy exists

**Q16a. Are tissues/samples/DNA available to other groups?**

No

**Q16b i) If yes, please describe below**

**Q16b. ii) In what form are tissues/samples/DNA supplied?**

**Q16b iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data (Q14 above)?**

No

**Q17. Is information on biological characteristics available to other groups?**

No

**Types:**

Case Control Studies

**Member States:**

France

**Diseases:**

Parkinson's disease & PD-related disorders

**Years:**

2016

**Database Categories:**

N/A

**Database Tags:**

N/A